Tiziana Life Sciences Secures ALS Association Grant for Innovative Therapy Trial Amid Competitive Financial Landsca...

New York, Nov. 19, 2024' Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a pioneering biotechnology company focused on developing transformative immunomodulation therapies, announced a significant milestone in their journey towards combating Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease. The ALS Association has approved Tiziana?s grant application under the prestigious Hoffman ALS Clinical Trial Awards Program, earmarking funding for a groundbreaking clinical trial involving the company's lead development candidate, intranasal foralumab.

Understanding the Grant and Clinical Trial s

The grant from the ALS Association will facilitate a 20-patient clinical trial aimed at assessing the safety and early-stage efficacy of intranasal foralumab, a fully human, anti-CD3 monoclonal antibody. Intranasal administration offers potential advantages by allowing the therapeutic agent to directly target the central nervous system while minimizing systemic exposure and related side effects.

The trial,

More Tiziana Life Sciences Ltd's News

Tiziana Life Sciences Ltd NIH Awards $4 Million Grant to Investigate Intranasal Anti-CD3 Monoclonal Antibody for Alzheimers Disease September 19, 2024

Tiziana Life Sciences Ltd Tiziana Life Sciences: An Innovative Breakthrough Paves the Way, but Financial Challenges Persist July 24, 2024

Tiziana Life Sciences Ltd Tiziana Receives $3.4 Million in Non-Dilutive Funding to Advance Neurodegenerative Disease Therapies June 28, 2024

Tiziana Life Sciences Ltd Fast Track Designation Approval and Orphan Drug Designation Request for Intranasal Foralumab in the Treatment of Non-... June 11, 2024

Tiziana Life Sciences Ltd Neuroimaging Correlates and Potential Therapeutic Mechanisms in Secondary Progressive Multiple Sclerosis: Six-... June 6, 2024

Tiziana Life Sciences Ltd Tiziana Life Sciences Pursues Grant for Clinical Trial of Intranasal Foralumab, Shares Surge Despite Financial Challenges June 4, 2024

Tiziana Life Sciences Ltd A Breakthrough Therapy for Non-Active Secondary Progressive Multiple Sclerosis: Intranasal Foralumab May 13, 2024

Tiziana Life Sciences Ltd Nasal Foralumab Treatment Shows Promising Results in Multiple Sclerosis Patients, Enhancing Brain Integrity April 25, 2024

More Product Service News News

Product Service News Matterport, a leader in 3D spatial data capture, has consistently demonstrated its commitment to innovation... December 2, 2024

Product Service News Beyond Air Secures CE Mark for LungFit PH System, Paving the Way for Advanced Treatment of Neonatal Respiratory Condi... December 2, 2024

Product Service News Rapid Responses OraSure Technologies Advances Marburg Virus Testing with Federal Backing, December 2, 2024

Previous News

LogicMark Partners with Black Knight Medical to Enhance Veteran Access to Critical Medical Alert Devices,

Gelteq Sets Sights on U.S. Market Strategic Expansion and Leadership Appointment of Adam Bendell Fueled by Innovation...

Dave Inc. Enters Strategic Partnership with Leading Sponsor Bank to Enhance Banking Services

Navigating Dreams and Data How Verizon Crafts Synergies in Partnerships and Corporate Growth,

Taboola and The Weather Company Join Forces A New Era of Digital Discovery and Engagement,

SEALing the Future WISeKeys Innovative Smartphone Fuses Web3 Security With Advanced Crypto Capabilities,

Revolutionizing Hearing The Promise of Fully Implanted Cochlear Technology

A New Era in Power Electronics Navitas and Richardson Electronics Propel Silicon Carbide Technology Forward in EMEA M...

GeoPark Breaks Ground Production Begins at Confluencia Norte in Argentina?s Vaca Muerta,

FIS and Oracle Forge Partnership to Advance Utility Billing Amidst Mixed Market Performance